Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Beijing Tiantan Biological Products Co., Ltd.    600161   CNE000000WF9

BEIJING TIANTAN BIOLOGICAL PRODUCTS CO.,

(600161)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Beijing Tiantan Biological Products Co., Ltd. : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
03/30/2020 | 09:15am EDT

The company will report its earnings for FY 2019 on 04/02/2020. Generally, the company reports earnings better than estimates. In recent months, the 3 analysts from Standard & Poor's consensus have revised their EPS estimates upward.


© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BEIJING TIANTAN BIOLOGICAL
03/30BEIJING TIANTAN BIOLOGICAL PRODUCTS : annual earnings release
2019BEIJING TIANTAN BIOLOGICAL PRODUCTS : annual earnings release
2018BEIJING TIANTAN BIOLOGICAL PRODUCTS : annual earnings release
More news
Financials (CNY)
Sales 2020 3 692 M
EBIT 2020 1 210 M
Net income 2020 711 M
Debt 2020 -
Yield 2020 0,36%
P/E ratio 2020 55,0x
P/E ratio 2021 44,8x
Capi. / Sales2020 10,6x
Capi. / Sales2021 9,12x
Capitalization 39 128 M
Chart BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Beijing Tiantan Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIJING TIANTAN BIOLOGICAL
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 38,50 CNY
Last Close Price 37,43 CNY
Spread / Highest target 2,86%
Spread / Average Target 2,86%
Spread / Lowest Target 2,86%
EPS Revisions
Managers
NameTitle
Dao Xing Fu General Manager & Director
Xiao Ming Yang Chairman
Jing Jin Zhu Chairman-Supervisory Board
Yi Zhang Chief Financial Officer & Deputy General Manager
Lian Qi Zhang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.33.97%5 297
CSL LIMITED11.56%88 649
BIOGEN INC.2.63%49 695
SAMSUNG BIOLOGICS CO.,LTD.45.96%33 689
ALEXION PHARMACEUTICALS-6.15%22 414
WUXI BIOLOGICS (CAYMAN) INC.28.23%21 227